{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:48:02Z","timestamp":1775728082323,"version":"3.50.1"},"reference-count":73,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21672050"],"award-info":[{"award-number":["21672050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803352"],"award-info":[{"award-number":["81803352"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds of the Central Universities","doi-asserted-by":"publisher","award":["JZ2020HGTB0052"],"award-info":[{"award-number":["JZ2020HGTB0052"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Polo-like kinase 4 (PLK4), a serine\/threonine kinase, is a member of the PLK family.\nAs a key regulator of the cell cycle, PLK4 controls centrosome duplication and mitosis. Abnormal\nPLK4\u2019s function can induce centrosome amplification, leading to tumorigenesis, therefore, PLK4\nhas been regarded as a promising target for cancer therapy, and PLK4 inhibitors have potentials to\ntreat multiple cancers and other PLK4-associated human disorders, such as myelodysplastic syndrome.\nIn addition, PLK4 may function as a DNA-damage sensitizer, therefore improving the\nefficacy of chemotherapy. To date, some small-molecule inhibitors with different chemical scaffolds\ntargeting PLK4 have been reported, among which, CFI-400945 has entered clinical trials for\nthe treatment of various solid tumors, myeloid leukemia, and myelodysplastic syndrome. In this\nreview, the structure and biological functions of PLK4 with other homologous PLKs are compared;\nthe roles of PLK4 in different cancers are reviewed; and PLK4 inhibitors disclosed in patent\nor literature are summarized. Used alone or in combination with other anticancer drugs in\npreclinical and clinical studies, PLK4 inhibitors have shown significant efficacy in the treatment\nof different cancers, demonstrating that PLK4 could be a critical target for cancer diagnosis and\ntherapy. However, our understanding of PLK4 is still limited, and novel mechanisms of PLK4\nshould be identified in future studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612828666220603124115","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:23:46Z","timestamp":1654255426000},"page":"67-79","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer:\nA Mini Patent Review"],"prefix":"10.2174","volume":"23","author":[{"given":"Zhouling","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University\nof Technology, Hefei, 230009, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7080-1768","authenticated-orcid":true,"given":"Chenzhong","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University\nof Technology, Hefei, 230009, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University\nof Technology, Hefei, 230009, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, the First Affiliated Hospital of\nAnhui Medical University, Hefei, 230022, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirong","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University\nof Technology, Hefei, 230009, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","volume":"20","author":"Attwood M.M.","year":"2021","unstructured":"Attwood M.M.; Fabbro D.; Sokolov A.V.; Knapp S.; Schi&#xF6;th H.B.; Trends in kinase drug discovery: Targets, indications and inhibitor design. Nat Rev Drug Discov 2021,20(11),839-861","journal-title":"Nat Rev Drug Discov"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","volume":"64","author":"Xie Z.","year":"2021","unstructured":"Xie Z.; Yang X.; Duan Y.; Han J.; Liao C.; Small-molecule kinase inhibitors for the treatment of nononcologic diseases. J Med Chem 2021,64(3),1283-1345","journal-title":"J Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","volume":"65","author":"Ayala-Aguilera C.C.","year":"2022","unstructured":"Ayala-Aguilera C.C.; Valero T.; Lorente-Mac&#xED;as &#xC1;.; Baillache D.J.; Croke S.; Unciti-Broceta A.; Small molecule kinase inhibitor drugs (1995-2021): Medical indication, pharmacology, and synthesis. J Med Chem 2022,65(2),1047-1131","journal-title":"J Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s11426-013-4963-0","volume":"56","author":"Liao C.","year":"2013","unstructured":"Liao C.; Yao R.; Diversity evolution and jump of Polo-like kinase 1 inhibitors. Sci China Chem 2013,56(10),1392-1401","journal-title":"Sci China Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrm3819","volume":"15","author":"Zitouni S.","year":"2014","unstructured":"Zitouni S.; Nabais C.; Jana S.C.; Guerrero A.; Bettencourt-Dias M.; Polo-like kinases: Structural variations lead to multiple functions. Nat Rev Mol Cell Biol 2014,15(7),433-452","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.tips.2015.08.013","volume":"36","author":"Lee K.S.","year":"2015","unstructured":"Lee K.S.; Burke T.R.; Park J.E.; Bang J.K.; Lee E.; Recent advances and new strategies in targeting Plk1 for anticancer therapy. Trends Pharmacol Sci 2015,36(12),858-877","journal-title":"Trends Pharmacol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/cells11050786","volume":"11","author":"Hoffmann I.","year":"2022","unstructured":"Hoffmann I.; Role of polo-like kinases Plk1 and Plk4 in the initiation of centriole duplication-impact on cancer. Cells 2022,11(5),786","journal-title":"Cells"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"587554","DOI":"10.3389\/fonc.2021.587554","volume":"11","author":"Zhang X.","year":"2021","unstructured":"Zhang X.; Wei C.; Liang H.; Han L.; Polo-like kinase 4's critical role in cancer development and strategies for Plk4-targeted therapy. Front Oncol 2021,11,587554","journal-title":"Front Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00432-019-02994-0","volume":"145","author":"Zhao Y.","year":"2019","unstructured":"Zhao Y.; Wang X.; PLK4: A promising target for cancer therapy. J Cancer Res Clin Oncol 2019,145(10),2413-2422","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/1061186X.2020.1818760","volume":"29","author":"Shakeel I.","year":"2021","unstructured":"Shakeel I.; Basheer N.; Hasan G.M.; Afzal M.; Hassan M.I.; Polo-like Kinase 1 as an emerging drug target: Structure, function and therapeutic implications. J Drug Target 2021,29(2),168-184","journal-title":"J Drug Target"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e0219691","DOI":"10.1371\/journal.pone.0219691","volume":"14","author":"Lee J.S.","year":"2019","unstructured":"Lee J.S.; Lee Y.; Andr&#xE9; E.A.; Lee K.J.; Nguyen T.; Feng Y.; Jia N.; Harris B.T.; Burns M.P.; Pak D.T.S.; Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer\u2019s disease model mice. PLoS One 2019,14(7),e0219691","journal-title":"PLoS One"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"9882","DOI":"10.18632\/aging.103253","volume":"12","author":"Li W.X.","year":"2020","unstructured":"Li W.X.; Li G.H.; Tong X.; Yang P.P.; Huang J.F.; Xu L.; Dai S.X.; Systematic metabolic analysis of potential target, therapeutic drug, diagnostic method and animal model applicability in three neurodegenerative diseases. Aging (Albany NY) 2020,12(10),9882-9914","journal-title":"Aging (Albany NY)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/cells9030740","volume":"9","author":"Hong C.T.","year":"2020","unstructured":"Hong C.T.; Chen K.Y.; Wang W.; Chiu J.Y.; Wu D.; Chao T.Y.; Hu C.J.; Chau K.D.; Bamodu O.A.; Insulin resistance promotes Parkinson\u2019s disease through aberrant expression of &#x3B1;-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells 2020,9(3),740","journal-title":"Cells"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1038\/sj.onc.1207425","volume":"23","author":"Bahassi M.","year":"2004","unstructured":"Bahassi M.; Hennigan R.F.; Myer D.L.; Stambrook P.J.; CDC25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation. Oncogene 2004,23(15),2658-2663","journal-title":"Oncogene"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1080\/15384101.2017.1373224","volume":"16","author":"Xu D.","year":"2017","unstructured":"Xu D.; Dai W.; Li C.; Polo-like kinase 3, hypoxic responses, and tumorigenesis. Cell Cycle 2017,16(21),2032-2036","journal-title":"Cell Cycle"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/onc.2015.105","volume":"35","author":"Helmke C.","year":"2016","unstructured":"Helmke C.; Becker S.; Strebhardt K.; The role of Plk3 in oncogenesis. Oncogene 2016,35(2),135-147","journal-title":"Oncogene"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.4161\/cc.10.14.16494","volume":"10","author":"de C&#xE1;rcer G.","year":"2011","unstructured":"de C&#xE1;rcer G.; Manning G.; Malumbres M.; From Plk1 to Plk5: Functional evolution of polo-like kinases. Cell Cycle 2011,10(14),2255-2262","journal-title":"Cell Cycle"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1128\/MCB.00607-10","volume":"31","author":"de C&#xE1;rcer G.","year":"2011","unstructured":"de C&#xE1;rcer G.; Escobar B.; Higuero A.M.; Garc&#xED;a L.; Ans&#xF3;n A.; P&#xE9;rez G.; Mollejo M.; Manning G.; Mel&#xE9;ndez B.; Abad-Rodr&#xED;guez J.; Malumbres M.; Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol 2011,31(6),1225-1239","journal-title":"Mol Cell Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/nar\/gkq011","volume":"38","author":"Andrysik Z.","year":"2010","unstructured":"Andrysik Z.; Bernstein W.Z.; Deng L.; Myer D.L.; Li Y.Q.; Tischfield J.A.; Stambrook P.J.; Bahassi M.; The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res 2010,38(9),2931-2943","journal-title":"Nucleic Acids Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14728222.2018.1410140","volume":"22","author":"Maniswami R.R.","year":"2018","unstructured":"Maniswami R.R.; Prashanth S.; Karanth A.V.; Koushik S.; Govindaraj H.; Mullangi R.; Rajagopal S.; Jegatheesan S.K.; PLK4: A link between centriole biogenesis and cancer. Expert Opin Ther Targets 2018,22(1),59-73","journal-title":"Expert Opin Ther Targets"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1535-7163.MCT-20-0741","volume":"20","author":"Garvey D.R.","year":"2021","unstructured":"Garvey D.R.; Chhabra G.; Ndiaye M.A.; Ahmad N.; Role of Polo-Like Kinase 4 (PLK4) in epithelial cancers and recent progress in its small molecule targeting for Cancer management. Mol Cancer Ther 2021,20(4),632-640","journal-title":"Mol Cancer Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1083\/jcb.201502088","volume":"209","author":"Moyer T.C.","year":"2015","unstructured":"Moyer T.C.; Clutario K.M.; Lambrus B.G.; Daggubati V.; Holland A.J.; Binding of STIL to Plk4 activates kinase activity to promote centriole assembly. J Cell Biol 2015,209(6),863-878","journal-title":"J Cell Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e07888","DOI":"10.7554\/eLife.07888","volume":"4","author":"Arquint C.","year":"2015","unstructured":"Arquint C.; Gabryjonczyk A.M.; Imseng S.; B&#xF6;hm R.; Sauer E.; Hiller S.; Nigg E.A.; Maier T.; STIL binding to Polo-box 3 of PLK4 regulates centriole duplication. eLife 2015,4,e07888","journal-title":"eLife"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"E657","DOI":"10.1073\/pnas.1417967112","volume":"112","author":"Klebba J.E.","year":"2015","unstructured":"Klebba J.E.; Buster D.W.; McLamarrah T.A.; Rusan N.M.; Rogers G.C.; Autoinhibition and relief mechanism for Polo-like kinase 4. Proc Natl Acad Sci USA 2015,112(7),E657-E666","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"11309","DOI":"10.1073\/pnas.1818820116","volume":"116","author":"Press M.F.","year":"2019","unstructured":"Press M.F.; Xie B.; Davenport S.; Zhou Y.; Guzman R.; Nolan G.P.; O\u2019Brien N.; Palazzolo M.; Mak T.W.; Brugge J.S.; Slamon D.J.; Role for polo-like kinase 4 in mediation of cytokinesis. Proc Natl Acad Sci USA 2019,116(23),11309-11318","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"188467","DOI":"10.1016\/j.bbcan.2020.188467","volume":"1875","author":"Raab C.A.","year":"2021","unstructured":"Raab C.A.; Raab M.; Becker S.; Strebhardt K.; Non-mitotic functions of polo-like kinases in cancer cells. Biochim Biophys Acta Rev Cancer 2021,1875(1),188467","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.semcdb.2020.04.019","volume":"110","author":"Jaiswal S.","year":"2021","unstructured":"Jaiswal S.; Singh P.; Centrosome dysfunction in human diseases. Semin Cell Dev Biol 2021,110,113-122","journal-title":"Semin Cell Dev Biol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"jcs241836","DOI":"10.1242\/jcs.241836","volume":"133","author":"Zhao H.","year":"2020","unstructured":"Zhao H.; Yang S.; Chen Q.; Duan X.; Li G.; Huang Q.; Zhu X.; Yan X.; Cep57 and Cep57l1 function redundantly to recruit the Cep63-Cep152 complex for centriole biogenesis. J Cell Sci 2020,133(13),jcs241836","journal-title":"J Cell Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1242\/jcs.129502","volume":"126","author":"Sonnen K.F.","year":"2013","unstructured":"Sonnen K.F.; Gabryjonczyk A.M.; Anselm E.; Stierhof Y.D.; Nigg E.A.; Human Cep192 and Cep152 cooperate in Plk4 recruitment and centriole duplication. J Cell Sci 2013,126(Pt 14),3223-3233","journal-title":"J Cell Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"E4849","DOI":"10.1073\/pnas.1319656110","volume":"110","author":"Kim T.S.","year":"2013","unstructured":"Kim T.S.; Park J.E.; Shukla A.; Choi S.; Murugan R.N.; Lee J.H.; Ahn M.; Rhee K.; Bang J.K.; Kim B.Y.; Loncarek J.; Erikson R.L.; Lee K.S.; Hierarchical recruitment of Plk4 and regulation of centriole biogenesis by two centrosomal scaffolds, Cep192 and Cep152. Proc Natl Acad Sci USA 2013,110(50),E4849-E4857","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e46054","DOI":"10.7554\/eLife.46054","volume":"8","author":"Moyer T.C.","year":"2019","unstructured":"Moyer T.C.; Holland A.J.; PLK4 promotes centriole duplication by phosphorylating STIL to link the procentriole cartwheel to the micro-tubule wall. eLife 2019,8,e46054","journal-title":"eLife"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e202002151","DOI":"10.1083\/jcb.202002151","volume":"220","author":"Chi W.","year":"2021","unstructured":"Chi W.; Wang G.; Xin G.; Jiang Q.; Zhang C.; PLK4-phosphorylated NEDD1 facilitates cartwheel assembly and centriole biogenesis initiations. J Cell Biol 2021,220(1),e202002151","journal-title":"J Cell Biol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10555-020-09937-z","volume":"40","author":"Mittal K.","year":"2021","unstructured":"Mittal K.; Kaur J.; Jaczko M.; Wei G.; Toss M.S.; Rakha E.A.; Janssen E.A.M.; S&#xF8;iland H.; Kucuk O.; Reid M.D.; Gupta M.V.; Aneja R.; Centrosome amplification: A quantifiable cancer cell trait with prognostic value in solid malignancies. Cancer Metastasis Rev 2021,40(1),319-339","journal-title":"Cancer Metastasis Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s42003-020-01161-3","volume":"3","author":"Kazazian K.","year":"2020","unstructured":"Kazazian K.; Haffani Y.; Ng D.; Lee C.M.M.; Johnston W.; Kim M.; Xu R.; Pacholzyk K.; Zih F.S.; Tan J.; Smrke A.; Pollett A.; Wu H.S.; Swallow C.J.; FAM46C\/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity. Commun Biol 2020,3(1),448","journal-title":"Commun Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"jcs238352","DOI":"10.1242\/jcs.238352","volume":"133","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Kim J.; Philip R.; Sridhar V.; Chandrashekhar M.; Moffat J.; van Breugel M.; Pelletier L.; Direct interaction between CEP85 and STIL mediates PLK4-driven directed cell migration. J Cell Sci 2020,133(8),jcs238352","journal-title":"J Cell Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"215619","DOI":"10.1016\/j.canlet.2022.215619","volume":"534","author":"Fontana F.","year":"2022","unstructured":"Fontana F.; Anselmi M.; Limonta P.; Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy. Cancer Lett 2022,534,215619","journal-title":"Cancer Lett"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/pros.24342","volume":"82","author":"Singh C.K.","year":"2022","unstructured":"Singh C.K.; Denu R.A.; Nihal M.; Shabbir M.; Garvey D.R.; Huang W.; Iczkowski K.A.; Ahmad N.; PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence. Prostate 2022,82(9),957-969","journal-title":"Prostate"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/1541-7786.MCR-20-0798","volume":"20","author":"Mittal K.","year":"2022","unstructured":"Mittal K.; Kaur J.; Sharma S.; Sharma N.; Wei G.; Choudhary I.; Imhansi-Jacob P.; Maganti N.; Pawar S.; Rida P.; Toss M.S.; Ales-kandarany M.; Janssen E.A.; Soiland H.; Gupta M.V.; Reid M.D.; Rakha E.A.; Aneja R.; Hypoxia drives centrosome amplification in cancer cells via HIF1&#x3B1;-dependent induction of polo-like Kinase 4. Mol Cancer Res 2022,20(4),596-606","journal-title":"Mol Cancer Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1593\/neo.12580","volume":"14","author":"Korzeniewski N.","year":"2012","unstructured":"Korzeniewski N.; Hohenfellner M.; Duensing S.; CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer. Neoplasia 2012,14(9),799-806","journal-title":"Neoplasia"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.3109\/10428194.2014.971407","volume":"56","author":"Ward A.","year":"2015","unstructured":"Ward A.; Sivakumar G.; Kanjeekal S.; Hamm C.; Labute B.C.; Shum D.; Hudson J.W.; The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies. Leuk Lymphoma 2015,56(7),2123-2133","journal-title":"Leuk Lymphoma"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e10734","DOI":"10.1097\/MD.0000000000010734","volume":"97","author":"Li S.","year":"2018","unstructured":"Li S.; Wang C.; Wang W.; Liu W.; Zhang G.; Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia. Medicine (Baltimore) 2018,97(20),e10734","journal-title":"Medicine (Baltimore)"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"144892","DOI":"10.1016\/j.gene.2020.144892","volume":"754","author":"Rahmani F.","year":"2020","unstructured":"Rahmani F.; Tadayyon Tabrizi A.; Hashemian P.; Alijannejad S.; Rahdar H.A.; Ferns G.A.; Hassanian S.M.; Shahidsales S.; Avan A.; Role of regulatory miRNAs of the Wnt\/&#x3B2;-catenin signaling pathway in tumorigenesis of breast cancer. Gene 2020,754,144892","journal-title":"Gene"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.7150\/jca.14307","volume":"7","author":"Li Z.","year":"2016","unstructured":"Li Z.; Dai K.; Wang C.; Song Y.; Gu F.; Liu F.; Fu L.; Expression of polo-like Kinase 4(PLK4) in breast cancer and its response to taxane-based neoadjuvant chemotherapy. J Cancer 2016,7(9),1125-1132","journal-title":"J Cancer"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41419-018-1071-2","volume":"9","author":"Lei Q.","year":"2018","unstructured":"Lei Q.; Xiong L.; Xia Y.; Feng Z.; Gao T.; Wei W.; Song X.; Ye T.; Wang N.; Peng C.; Li Z.; Liu Z.; Yu L.; YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death Dis 2018,9(11),1066","journal-title":"Cell Death Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.breast.2021.03.011","volume":"58","author":"Parsyan A.","year":"2021","unstructured":"Parsyan A.; Cruickshank J.; Hodgson K.; Wakeham D.; Pellizzari S.; Bhat V.; Cescon D.W.; Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer. Breast 2021,58,6-9","journal-title":"Breast"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41419-017-0088-2","volume":"9","author":"Tian X.","year":"2018","unstructured":"Tian X.; Zhou D.; Chen L.; Tian Y.; Zhong B.; Cao Y.; Dong Q.; Zhou M.; Yan J.; Wang Y.; Qiu Y.; Zhang L.; Li Z.; Wang H.; Wang D.; Ying G.; Zhao Q.; Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K\/Akt signaling pathway. Cell Death Dis 2018,9(2),54","journal-title":"Cell Death Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1111\/jcmm.14996","volume":"24","author":"Wang J.","year":"2020","unstructured":"Wang J.; Ren D.; Sun Y.; Xu C.; Wang C.; Cheng R.; Wang L.; Jia G.; Ren J.; Ma J.; Tu Y.; Ji H.; Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN\/PI3K\/AKT\/mTOR signalling pathway. J Cell Mol Med 2020,24(7),3931-3947","journal-title":"J Cell Mol Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"111190","DOI":"10.18632\/oncotarget.22704","volume":"8","author":"Sredni S.T.","year":"2017","unstructured":"Sredni S.T.; Bailey A.W.; Suri A.; Hashizume R.; He X.; Louis N.; Gokirmak T.; Piper D.R.; Watterson D.M.; Tomita T.; Inhibition of polo-like kinase 4 (PLK4): A new therapeutic option for rhabdoid tumors and pediatric medulloblastoma. Oncotarget 2017,8(67),111190-111212","journal-title":"Oncotarget"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"7997","DOI":"10.2147\/OTT.S258616","volume":"13","author":"Pu J.T.","year":"2020","unstructured":"Pu J.T.; Hu Z.; Zhang D.G.; Zhang T.; He K.M.; Dai T.Y.; MiR-654-3p suppresses non-small cell lung cancer tumourigenesis by inhi-biting PLK4. OncoTargets Ther 2020,13,7997-8008","journal-title":"OncoTargets Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e41293","DOI":"10.1371\/journal.pone.0041293","volume":"7","author":"Liu L.","year":"2012","unstructured":"Liu L.; Zhang C.Z.; Cai M.; Fu J.; Chen G.G.; Yun J.; Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 2012,7(7),e41293","journal-title":"PLoS One"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.hpb.2020.07.003","volume":"23","author":"Abreu P.","year":"2021","unstructured":"Abreu P.; Ivanics T.; Jiang K.; Chen K.; E Hansen B.; Sapisochin G.; Ghanekar A.; Novel biomarker for hepatocellular carcinoma: High tumoral PLK-4 expression is associated with better prognosis in patients without microvascular invasion. HPB (Oxford) 2021,23(3),359-366","journal-title":"HPB (Oxford)"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6476","DOI":"10.1002\/cam4.2487","volume":"8","author":"Meng L.","year":"2019","unstructured":"Meng L.; Zhou Y.; Ju S.; Han J.; Song C.; Kong J.; Wu Y.; Lu S.; Xu J.; Yuan W.; Zhang E.; Wang C.; Hu Z.; Gu Y.; Luo R.; Wang X.; A cis-eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma. Cancer Med 2019,8(14),6476-6484","journal-title":"Cancer Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41419-018-1020-0","volume":"9","author":"Bao J.","year":"2018","unstructured":"Bao J.; Yu Y.; Chen J.; He Y.; Chen X.; Ren Z.; Xue C.; Liu L.; Hu Q.; Li J.; Cui G.; Sun R.; MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR\/CHEK1 pathway. Cell Death Dis 2018,9(10),1045","journal-title":"Cell Death Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"111099","DOI":"10.1016\/j.biopha.2020.111099","volume":"134","author":"Zhang N.","year":"2021","unstructured":"Zhang N.; Hu X.; Du Y.; Du J.; The role of miRNAs in colorectal cancer progression and chemoradiotherapy. Biomed Pharmacother 2021,134,111099","journal-title":"Biomed Pharmacother"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3892\/ijo.2018.4659","volume":"54","author":"Liao Z.","year":"2019","unstructured":"Liao Z.; Zhang H.; Fan P.; Huang Q.; Dong K.; Qi Y.; Song J.; Chen L.; Liang H.; Chen X.; Zhang Z.; Zhang B.; High PLK4 expression promotes tumor progression and induces epithelial mesenchymal transition by regulating the Wnt\/&#x3B2; catenin signaling pathway in colorectal cancer. Int J Oncol 2019,54(2),479-490","journal-title":"Int J Oncol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/2211-5463.13262","volume":"11","author":"Yang Z.","year":"2021","unstructured":"Yang Z.; Sun H.; Ma W.; Wu K.; Peng G.; Ou T.; Wu S.; Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activa-tion of the p38\/p53\/p21 signaling pathway in bladder cancer. FEBS Open Bio 2021,11(9),2631-2646","journal-title":"FEBS Open Bio"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41419-021-03919-x","volume":"12","author":"Zhao Y.","year":"2021","unstructured":"Zhao Y.; Yang J.; Liu J.; Cai Y.; Han Y.; Hu S.; Ren S.; Zhou X.; Wang X.; Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma. Cell Death Dis 2021,12(7),640","journal-title":"Cell Death Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/cells10051176","volume":"10","author":"Kressin M.","year":"2021","unstructured":"Kressin M.; Fietz D.; Becker S.; Strebhardt K.; Modelling the functions of polo-like kinases in mice and their applications as cancer targets with a special focus on Ovarian Cancer. Cells 2021,10(5),1176","journal-title":"Cells"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/carcin\/bgy175","volume":"40","author":"Kelleher F.C.","year":"2019","unstructured":"Kelleher F.C.; Kroes J.; Lewin J.; Targeting the centrosome and polo-like kinase 4 in osteosarcoma. Carcinogenesis 2019,40(4),493-499","journal-title":"Carcinogenesis"},{"key":"ref=60","author":"Brenchley G.","year":"2007","unstructured":"Brenchley G.; Charrier J.-D.; Durrant S.; Knegtel R.; Ramaya S.; Sadiq S.; Thiophene-carboxamides useful as inhibitors of protein kinases. W.O. Patent 2007139795A1, May 22, 2007"},{"key":"ref=61","author":"Feger D.","year":"2009","unstructured":"Feger D.; Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors. W.O. Patent 2009047216A2, April 16, 2009"},{"key":"ref=62","author":"Diels G.S.M.","year":"2009","unstructured":"Diels G.S.M.; Ten Holte P.; Freyne E.J.E.; Grand-Perret T.A.R.; Van Emelen K.; Embrechts W.C.J.; Bonnet P.G.A.; Pyrrolopyrimidine derivatives as polo-like kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. W.O. Patent 2009016132A1, February 5, 2009"},{"key":"ref=63","author":"Buijnsters P.J.J.A.","year":"2009","unstructured":"Buijnsters P.J.J.A.; Verdonck M.G.C.; Van Emelen K.; Bonnet P.G.A.; 4-Aryl-2-anilinopyrimidines as PLK kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of kinase-mediated diseases. W.O. Patent 2009112439A1, September 17, 2009"},{"key":"ref=64","author":"Pauls H.W.","year":"2009","unstructured":"Pauls H.W.; Forrest B.T.; Laufer R.; Feher M.; Sampson P.B.; Pan G.; Preparation of indazolyl, benzimidazolyl, benzotriazolyl substituted indolin-2-one derivatives as kinase inhibitors useful in the treatment of cancer. W.O. Patent 2009079767A1, July 2, 2009"},{"key":"ref=65","author":"Sampson P.B.","year":"2011","unstructured":"Sampson P.B.; Liu Y.; Li S.-W.; Forrest B.T.; Pauls H.W.; Edwards L.G.; Feher M.; Patel N.K.B.; Laufer R.; Pan G.; (1HIndazol- 6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one derivatives as protein kinase inhibitors and their preparation and use for the treatment of cancer. W.O. Patent 2011123946A1, October 13, 2011"},{"key":"ref=66","author":"Pauls H.W.","year":"2013","unstructured":"Pauls H.W.; Laufer R.; Liu Y.; Li S.-W.; Forrest B.T.; Lang Y.; Patel N.K.B.; Edwards L.G.; Ng G.; Sampson P.B.; Feher M.; Awrey D.E.; Indazole compounds as kinase inhibitors and their preparation and method of treating cancer. W.O. Patent 2013053051A1, April 18, 2013"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"27737","DOI":"10.1039\/C7RA02518A","volume":"7","author":"Liu Z.H.","year":"2017","unstructured":"Liu Z.H.; Lei Q.; Wei W.; Xiong L.; Shi Y.J.; Yan G.Y.; Gao C.; Ye T.H.; Wang N.Y.; Yu L.T.; Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1H-indazol-6-yl) pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer. RSC Advances 2017,7(44),27737-27746","journal-title":"RSC Advances"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"Hu-Lowe D.D.","year":"2008","unstructured":"Hu-Lowe D.D.; Zou H.Y.; Grazzini M.L.; Hallin M.E.; Wickman G.R.; Amundson K.; Chen J.H.; Rewolinski D.A.; Yamazaki S.; Wu E.Y.; McTigue M.A.; Murray B.W.; Kania R.S.; O\u2019Connor P.; Shalinsky D.R.; Bender S.L.; Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008,14(22),7272-7283","journal-title":"Clin Cancer Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1002\/ijc.25611","volume":"128","author":"R&#xF6;ssler J.","year":"2011","unstructured":"R&#xF6;ssler J.; Monnet Y.; Farace F.; Opolon P.; Daudigeos-Dubus E.; Bourredjem A.; Vassal G.; Geoerger B.; The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Int J Cancer 2011,128(11),2748-2758","journal-title":"Int J Cancer"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1021\/ml300351e","volume":"4","author":"Liu J.J.","year":"2013","unstructured":"Liu J.J.; Higgins B.; Ju G.; Kolinsky K.; Luk K.C.; Packman K.; Pizzolato G.; Ren Y.; Thakkar K.; Tovar C.; Zhang Z.; Wovkulich P.M.; Discovery of a highly potent, orally active mitosis\/angiogenesis inhibitor r1530 for the treatment of solid tumors. ACS Med Chem Lett 2013,4(2),259-263","journal-title":"ACS Med Chem Lett"},{"key":"ref=71","author":"Gahman T.","year":"2016","unstructured":"Gahman T.; Shiau A. K.; Preparation of substituted pyrimidinamines as PLK4 inhibitors for treating cancer. W.O. Patent 2016166604A1, October 20, 2016"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1126\/science.aaa5111","volume":"348","author":"Wong Y.L.","year":"2015","unstructured":"Wong Y.L.; Anzola J.V.; Davis R.L.; Yoon M.; Motamedi A.; Kroll A.; Seo C.P.; Hsia J.E.; Kim S.K.; Mitchell J.W.; Mitchell B.J.; Desai A.; Gahman T.C.; Shiau A.K.; Oegema K.; Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science 2015,348(6239),1155-1160","journal-title":"Science"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41416-019-0517-3","volume":"121","author":"Veitch Z.W.","year":"2019","unstructured":"Veitch Z.W.; Cescon D.W.; Denny T.; Yonemoto L.M.; Fletcher G.; Brokx R.; Sampson P.; Li S.W.; Pugh T.J.; Bruce J.; Bray M.R.; Slamon D.J.; Mak T.W.; Wainberg Z.A.; Bedard P.L.; Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: A phase 1 dose-escalation trial. Br J Cancer 2019,121(4),318-324","journal-title":"Br J Cancer"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220603124115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205614\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220603124115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T12:49:36Z","timestamp":1678970976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205614\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612828666220603124115","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}